UPCOMING SESSIONS in ET
Tue, Jun 23, 2026
5:00 – 6:00 AM Bangkok
Being Honest about your Symptoms without feeling like your Complaining Martha Hodges Click To Register
UPCOMING SESSIONS in ET
Tue, Jun 23, 2026 · 5:00 – 6:00 AM Bangkok
Being Honest about your Symptoms without feeling like your Complaining
Martha Hodges
Click To Register
View all sessions

News

ctv
Jun 03, 2026
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Details and patient eligibilityAboutThis study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in…
Read more
science direct
Jun 02, 2026
“Transthyretin amyloidosis following domino liver transplantation: a case report.”
INTRODUCTIONAcquired transthyretin amyloidosis (ATTR) represents a rare but recognized complication in recipients of domino liver transplants (DLT) from donors…
Read more
Rare Disease Advisor
Jun 02, 2026
Transferability of ICD-10 Machine Learning Models Is Limited in ATTR-CM Screening
The cross-border transfer of machine learning models based on the International Classification of Diseases, 10th revision (ICD-10) for the identification of rare…
Read more
Oxford Academic
Jun 02, 2026
Affordability of Innovation –Cost-effectiveness and Budget Impact Analysis of Acoramidis in Transthyretin Amyloid Cardiomyopathy in the German Health-care System
AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) causes heart failure with substantial morbidity, mortality, and healthcare utilization. ATTRibute-…
Read more
Rare Disease Advisor
Jun 02, 2026
Symptoms of Heart Failure Should Prompt Suspicion of ATTR-CM
There are substantial delays from the time of incident heart failure to a diagnosis of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), according to a new…
Read more
amyloidosis
Jun 01, 2026
Nerve damage marker tied to hATTR-PN symptom severity in new study
Increased levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with more severe neurological symptoms in people with hereditary…
Read more
pharmaphorum
Jun 01, 2026
ASCO26: Could AL amyloidosis see a new crop of therapies?
Potential antibody therapies from AstraZeneca and Regeneron for light chain (AL) amyloidosis had new data at ASCO, raising the prospect of new treatments for the…
Read more
Subscribe to